OF ANTIRETROVIRAL THERAPY Efficacy and Safety of Simplifying from a Regimen of Contacts for further Atazanavir + Ritonavir + information: Tenofovir/Emtricitabine to Milagros Rodriguez Atazanavir + 305/576-1234 ext 244 Abacavir/Lamivudine Without Ritonavir for 48 MEDICATION TRIALS: GlaxoSmithKline -EPZ113734: PI: Steven Santiago, M.D. Enrollment Open MEDICATION TRIALS: Treatment Treatment experienced (history A prospective, randomized, experienced (history of Current or Past of Current or Past Use of multicenter, open-label study to Contacts for further Use of Antiretroviral Therapy) Antiretroviral Therapy) compare the efficacy and safety information: of simplifying from a regimen of Eligibility: Atazanavir + 305/576-1234 ext 276 18 yrs of age who have been undetectable Ritonavir/Tenofovir/ for more than 3 months and receiving a Emtricitabine to Atazanavir + or regimen of ATV/RTV (300mg/100 mg) Abacavir/ Lamivudine without Milagros Rodriguez +TDF/FTC (300mg/200 mg) as initial or first Ritonovir for 48 weeks in 305/576-1234 ext 244 and only switch regimen for at least 6 virologically suppressed, months. HLA-B 5701 negative subjects
OF ANTIRETROVIRAL THERAPY Efficacy and Safety of Simplifying from a Regimen of Atazanavir + Ritonavir + Tenofovir/Emtricitabine to Atazanavir + Abacavir/Lamivudine Without Ritonavir for 48 Contacts for further information: Milagros Rodriguez 305/576-1234 ext 244 MEDICATION TRIALS: Treatment experienced (history of Current or Past Use of Antiretroviral Therapy) GlaxoSmithKline -EPZ113734: A prospective, randomized, multicenter, open-label study to compare the efficacy and safety of simplifying from a regimen of Atazanavir + Ritonavir/Tenofovir/ Emtricitabine to Atazanavir + Abacavir/ Lamivudine without Ritonovir for 48 weeks in virologically suppressed, HLA-B 5701 negative subjects PI: Steven Santiago, M.D. Contacts for further information: 305/576-1234 ext 276 or Milagros Rodriguez 305/576-1234 ext 244 Enrollment Open MEDICATION TRIALS: Treatment experienced (history of Current or Past Use of Antiretroviral Therapy) Eligibility: 18 yrs of age who have been undetectable for more than 3 months and receiving a regimen of ATV/RTV (300mg/100 mg) +TDF/FTC (300mg/200 mg) as initial or first and only switch regimen for at least 6 months.